A diagnostic dilemma: Atypical melanocytic lesions arising in the setting of treatment with the BRAF inhibitor, vemurafenib - Mary Clark, MD; Paul Imbriano, DO; Michael Harwood, MD; Klaus Busam, MD; Leslie Robinson-Bostom, MD (Elsevier, 2022)